Reviewer's report

**Title:** A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinoconjunctivitis with or without asthma

**Version:** 1  **Date:** 7 March 2013

**Reviewer number:** 1

**Reviewer's report:**

The authors do address the potential causes of the lack of clinical effect. I would have liked to have see a breakdown in the RQLQ if there are impact on the ocular versus nasal domains as a subdivision.

The only minor comment is that pollen grains are to reported as whole numbers and cannot be reported to 2 decimal places.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.